Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists decode hidden links in deadly tropical infection

NCT ID NCT07345910

Knowledge-focused Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 3 times

Summary

This study aims to understand how the environment, the bacteria that cause melioidosis, and the human body interact to cause disease. Researchers will follow about 1,000 infected patients and 1,000 healthy matched controls in Thailand, Laos, and Cambodia for one year. They will also monitor a high-risk village to catch hidden infections and learn how to prevent them.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Melioidosis patients: Patients confirmed to have melioidosis. Healthy controls: For each confirmed melioidosis case, a healthy control-defined as having no current fever, no evidence of soft tissue infection, and no prior history of melioidosis-will be recruited from satellite blood bank donors within approximately two weeks of case identification. Controls will be matched by age (±5 years), sex, and village of residence. Sandbox Village residents: All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for melioidosis patients: * Age ≥20 years * Positive for Burkholderia pseudomallei from any clinical samples * Resident of the study area for at least two years, including the follow-up period * Willing to participate and give informed consent. Inclusion criteria for healthy controls: * Age ≥20 years * Currently healthy as judged by study doctor * Resident of the study area for at least two years, including the follow-up period * Willing to participate and give informed consent. Inclusion criteria for sandbox residents: * Age ≥20 years * Resident of the study area for at least two years, including the follow-up period * Willing to participate and give informed consent. Exclusion criteria for melioidosis patients: * Current tuberculosis (TB) or TB treatment within the past six months * Documented HIV infection or use of immunosuppressive therapy in the past 12 months Exclusion criteria for healthy controls: * History of melioidosis * Significant acute illness * Current fever or soft tissue infection Exclusion criteria for sandbox residents -N/A

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melioidosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melioidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melioidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cambodia-Oxford Medical Research Unit (COMRU)

    NOT_YET_RECRUITING

    Siem Reap, Cambodia

  • Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)

    NOT_YET_RECRUITING

    Vientiane, Laos

  • Sunpasitthiprosong Hospital

    RECRUITING

    Ubon Ratchathani, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.